Systemic Lupus Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Systemic Lupus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 200 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled219 locationsNCT06617325
Recruiting
Phase 2

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)
Hangzhou Sumgen Biotech Co., Ltd.120 enrolled1 locationNCT07447986
Recruiting
Phase 1

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

Rheumatoid ArthritisSystemic Lupus Erythematosus
Merck Sharp & Dohme LLC21 enrolled4 locationsNCT07363590
Recruiting

Patient-Centered Assessment of Symptoms and Outcomes

Myalgic Encephalomyelitis/Chronic Fatigue SyndromeCancerFatigue+5 more
National Center for Complementary and Integrative Health (NCCIH)692 enrolled1 locationNCT03952624
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting

Study of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2,000 enrolled1 locationNCT00001372
Recruiting
Phase 4

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Bristol-Myers Squibb35 enrolled4 locationsNCT06875960
Recruiting
Phase 1

A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

Rheumatoid ArthritisHealthy VolunteersSystemic Lupus Erythematosus
Capstan Therapeutics64 enrolled1 locationNCT06917742
Recruiting
Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 1

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus
Climb Bio, Inc.30 enrolled18 locationsNCT07011043
Recruiting
Phase 1Phase 2

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Childhood-onset Systemic Lupus Erythematous
Cartesian Therapeutics50 enrolled2 locationsNCT07089121
Recruiting

Anifrolumab Malignancy and Serious Infections Study

Systemic Lupus Erythematosus
AstraZeneca3,195 enrolled4 locationsNCT07000110
Recruiting
Phase 1

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Rheumatoid ArthritisHealthySystemic Lupus Erythematosus
Eli Lilly and Company63 enrolled7 locationsNCT07276958
Recruiting
Early Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases

Systemic Lupus Erythematosus (SLE)Rheumatic DiseasesPediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)+1 more
The Children's Hospital of Zhejiang University School of Medicine36 enrolled1 locationNCT07490041
Recruiting

The Anifrolumab PRIM Program

Systemic Lupus Erythematosus
AstraZeneca240 enrolled1 locationNCT06795893
Recruiting
Phase 1

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Lupus Nephritis (LN)Systemic Lupus Erthematosus (SLE)Extra-renal Lupus (ERL)
Hinge Bio30 enrolled1 locationNCT07491900
Recruiting
Phase 1

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)
Sanofi62 enrolled8 locationsNCT06647069
Recruiting
Phase 1

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

SLESLE (Systemic Lupus)
Cullinan Therapeutics Inc.24 enrolled15 locationsNCT06613360
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
AstraZeneca72 enrolled33 locationsNCT06916806
Recruiting

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Systemic Lupus Erythematosus
AstraZeneca442 enrolled1 locationNCT06659029